Medicine
(Jul 2023)
Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
Shaohua Zhang,
Jianbin Li,
Ruonan Xu,
Qianjun Chen,
Gang Sun,
Ying Lin,
Feng Jin,
Xinlan Liu,
Zhimin Fan,
Yiding Chen,
Yali Cao,
Xinzheng Li,
Jianyun Nie,
Guiying Xu,
Xiaojia Wang,
Yuee Teng,
Tao Sun,
Hong Liu,
Jing Luo,
Cuizhi Geng,
Man Li,
Ting Luo,
Yinhua Liu,
Fu-Sheng Wang,
Zefei Jiang,
Wang Haijuan
Affiliations
Shaohua Zhang
1 Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China
Jianbin Li
1 Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China
Ruonan Xu
2 Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Qianjun Chen
3 Department of Breast Cancer, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510000, China
Gang Sun
4 Department of Breast Head and Neck Surgery, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China
Ying Lin
5 Department of Breast Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, China
Feng Jin
6 Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang 110001, China
Xinlan Liu
7 Department of Oncology, General Hospital of Ningxia Medical University, Ningxia 750003, China
Zhimin Fan
8 Department of Breast Surgery, the First Hospital of Jilin University, Changchun 130031, China
Yiding Chen
9 Department of Oncology Surgery, the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou 310009, China
Yali Cao
10 Department of Oncology, Nanchang Third Hospital, Nanchang 330009, China
Xinzheng Li
11 Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan 030013, China
Jianyun Nie
12 Department of Breast Surgery, Yunnan Cancer Hospital, Kunming 650118, China
Guiying Xu
13 Department of Breast Surgery, Jilin Cancer Hospital, Changchun 130012, China
Xiaojia Wang
14 Department of Oncology, Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou 310005, China
Yuee Teng
15 Department of Oncology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China
Tao Sun
16 Department of Oncology, Liaoning Cancer Hospital, Shenyang 110801, China
Hong Liu
17 Department of Oncology, Tumor Hospital of Tianjin Medical University, Tianjin 300060, China
Jing Luo
18 Department of Breast Surgery, Sichuan Provincial People's Hospital, Chengdu 610042, China
Cuizhi Geng
19 Department of Breast Cancer, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
Man Li
20 Department of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian 116050, China
Ting Luo
21 Department of Head and Neck Tumor, West China Hospital of Sichuan University, Chengdu 610042, China
Yinhua Liu
22 Department of Breast Surgery, the First Hospital of Peking University, Beijing 100034, China.
Fu-Sheng Wang
2 Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Zefei Jiang
1 Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China
Wang Haijuan
DOI
https://doi.org/10.1097/ID9.0000000000000090
Journal volume & issue
Vol. 3,
no. 3
Abstract
Read online
Abstract. In this study, we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019 (COVID-19) vaccination. The patients were recruited from 41 hospitals across 20 Chinese provinces. The vaccination coverage was approximately 22.4%, and the frequency of total adverse events was 13.3% after the first dose and 9.9% after the second dose. The most frequent adverse reaction within 14 days of the first dose was local pain (5.7%). Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age (odds ratio [OR], 1.238; 95% confidence interval [CI], 1.101–1.391), chronic disease history (OR, 1.189; 95% CI, 1.057–1.337), and cancer relapse (OR, 1.398; 95% CI, 1.233–1.585). Of the unvaccinated patients with breast cancer, 54.1% opted to receive COVID-19 vaccines if more data were available. Considering the safety but low vaccination coverage for breast cancer, increased positive attitudes and acceptance toward COVID-19 vaccines are important.
WeChat QR code
Close
